Evidence map›Paper›PMID 40496440›Full record

ArticleJHEP reports : innovation in hepatology2025

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease.

Amber G Bozward, Scott P Davies, Rémi Fiancette, Grace E Wootton, Sian Faustini, Hin Fai Kwok, Naomi Richardson, Sean M Morris, Kayani Kayani, Gary Middleton and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amber G BozwardDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Scott P DaviesDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Rémi FiancetteDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Grace E WoottonDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Sian FaustiniClinical Immunology Service, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Hin Fai KwokClinical Immunology Service, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Naomi RichardsonDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Sean M MorrisDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Kayani KayaniDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Gary MiddletonInstitute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Ye H OoDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Effective control of chronic liver diseases (CLD) requires suppression of effector T cells by CD4 Methods: Liver infiltrating (CLD explants n = 7, donor liver n = 4) and peripheral (CLD blood n = 22, healthy control blood n = 10) TIGIT Results: TIGIT Conclusions: TIGIT Impact and implications: We identified a highly suppressive subset of regulatory T cells in the liver, defined as TIGIT

Indexed as

AutoimmuneCheckpoint inhibitorCTLA-4IL-2Immunotherapy

Identifiers

PMID40496440
PMCPMC12151200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.